Gyre Therapeutics, Inc. (GYRE)
4.555
-1.86
(-28.94%)
USD |
NASDAQ |
Oct 30, 16:00
4.64
+0.08
(+1.87%)
After-Hours: 20:00
Gyre Therapeutics EPS Diluted (Quarterly) : -0.1159 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1159 |
| March 31, 2026 | -0.0961 |
| December 31, 2025 | -0.0189 |
| September 30, 2025 | 0.0349 |
| June 30, 2025 | -0.0253 |
| March 31, 2025 | 0.0043 |
| December 31, 2024 | -0.0034 |
| September 30, 2024 | 0.0131 |
| June 30, 2024 | 0.0338 |
| March 31, 2024 | 0.0734 |
| December 31, 2023 | -1.066 |
| September 30, 2023 | 0.7559 |
| June 30, 2023 | 0.3522 |
| March 31, 2023 | 0.4265 |
| December 31, 2022 | -9.543 |
| September 30, 2022 | -2.327 |
| June 30, 2022 | 24.60 |
| March 31, 2022 | -6.932 |
| December 31, 2021 | -9.708 |
| September 30, 2021 | -12.06 |
| June 30, 2021 | -9.535 |
| March 31, 2021 | -11.86 |
| December 31, 2020 | -12.83 |
| September 30, 2020 | -10.90 |
| June 30, 2020 | -14.46 |
| Date | Value |
|---|---|
| March 31, 2020 | -4.166 |
| December 31, 2019 | -16.95 |
| September 30, 2019 | -15.85 |
| June 30, 2019 | -17.24 |
| March 31, 2019 | -18.91 |
| December 31, 2018 | -13.60 |
| September 30, 2018 | -9.664 |
| June 30, 2018 | -8.10 |
| March 31, 2018 | -8.40 |
| December 31, 2017 | -14.40 |
| September 30, 2017 | -20.16 |
| June 30, 2017 | -38.02 |
| March 31, 2017 | -68.51 |
| December 31, 2016 | -70.16 |
| September 30, 2016 | -90.61 |
| June 30, 2016 | -95.00 |
| March 31, 2016 | -70.71 |
| December 31, 2015 | -100.98 |
| September 30, 2015 | -210.04 |
| June 30, 2015 | -7245.36 |
| March 31, 2015 | -12084.52 |
| December 31, 2014 | -5528.19 |
| September 30, 2014 | -6426.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | -693.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Cytokinetics, Inc. | -1.505 |
| Incyte Corp. | -3.861 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.27M |
| Revenue (Quarterly) | 29.10M |
| Total Expenses (Quarterly) | 39.71M |
| Enterprise Value | 468.60M |
| Gross Profit Margin (Quarterly) | 92.41% |
| Profit Margin (Quarterly) | -49.03% |
| Earnings Yield | -4.30% |
| Normalized Earnings Yield | -3.873 |